P-139 Comparison of cost-effectiveness of anti-epidermal growth factor receptor monoclonal antibody and anti-vascular endothelial growth factor monoclonal antibody in K-RAS WT, RAS WT, and RAS WT left-sided metastatic colorectal cancer

Abstract

Metastatic colorectal cancer (mCRC) is a significant global health burden. Combination chemotherapy plus targeted therapy, either anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibody (mAb) or anti-vascular endothelial growth factor (anti-VEGF) mAb have become the current standard first-line treatment. Both kinds of targeted therapy have demonstrated their efficacies as first-line therapies in K-RAS wild-type (WT) patients. We aimed to compare the economic value of chemotherapy plus anti-EGFR mAb against chemotherapy with bevacizumab (an anti-VEGF mAb) in K-RAS WT, RAS WT, and RAS WT left-sided mCRC patients from a Hong Kong societal perspective.